CHIARINI, Francesca
 Distribuzione geografica
Continente #
NA - Nord America 1.887
EU - Europa 1.043
AS - Asia 973
SA - Sud America 8
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.914
Nazione #
US - Stati Uniti d'America 1.883
SG - Singapore 523
IT - Italia 302
HK - Hong Kong 225
SE - Svezia 161
RU - Federazione Russa 154
GB - Regno Unito 150
CN - Cina 135
ID - Indonesia 66
DE - Germania 63
LT - Lituania 52
FI - Finlandia 38
NL - Olanda 38
IE - Irlanda 30
AT - Austria 16
FR - Francia 9
BR - Brasile 6
TR - Turchia 5
BG - Bulgaria 4
CZ - Repubblica Ceca 4
JP - Giappone 4
UA - Ucraina 4
ES - Italia 3
RO - Romania 3
AZ - Azerbaigian 2
CA - Canada 2
LA - Repubblica Popolare Democratica del Laos 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
VN - Vietnam 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AR - Argentina 1
AU - Australia 1
BD - Bangladesh 1
BE - Belgio 1
CH - Svizzera 1
CO - Colombia 1
GE - Georgia 1
IN - India 1
IQ - Iraq 1
IS - Islanda 1
LV - Lettonia 1
MD - Moldavia 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PL - Polonia 1
Totale 3.914
Città #
Santa Clara 1.071
Singapore 358
Ashburn 270
Hong Kong 223
Nyköping 145
Jakarta 66
Chandler 58
Fairfield 56
Moscow 47
London 42
Houston 37
Helsinki 34
Woodbridge 32
Dublin 30
Southend 30
Bologna 29
Parma 29
Milan 27
Shanghai 23
Nuremberg 21
Amsterdam 20
Beijing 20
Cambridge 19
Seattle 17
Reggio Emilia 16
Wilmington 16
Modena 12
Munich 12
Washington 12
Dallas 11
Kilburn 11
Padova 10
Chiswick 9
Los Angeles 9
Rome 9
Ann Arbor 8
Assago 8
New York 8
San Diego 8
Vienna 8
Ferrara 7
Hounslow 7
Islington 7
Naples 7
Torre del Greco 7
Glasgow 6
Carpi 5
Dearborn 5
Frankfurt am Main 5
Arceto 4
Brno 4
Jacksonville 4
Prescot 4
Princeton 4
Sofia 4
Wuhan 4
Boardman 3
Catania 3
Chicago 3
Council Bluffs 3
Eugene 3
Guangzhou 3
Lappeenranta 3
Paris 3
Perugia 3
Romola 3
Southwark 3
Stockholm 3
Venice 3
Aberdare 2
Asaka 2
Baku 2
Bloomington 2
Bratislava 2
Brentford 2
Curtatone 2
Dong Ket 2
Falls Church 2
Frattamaggiore 2
Genoa 2
Giuliano di Roma 2
Gualtieri 2
Istanbul 2
Izmir 2
La Spezia 2
Madrid 2
Montecatini Terme 2
Newark 2
Nola 2
Pescara 2
Portici 2
Ravenna 2
Rimini 2
Roncoferraro 2
Turin 2
Urbino 2
Vientiane 2
Wandsworth 2
Zhengzhou 2
Acton 1
Totale 3.055
Nome #
Dual inhibition of PI3K/mTOR signaling in chemoresistant AMLprimary cells. 230
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: Turning offthe prosurvival ER chaperone BIP/Grp78 and turning on the proapoptotic NF-κB 156
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer 156
Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance 118
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 108
The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine 81
Targeting metabolic vulnerabilities and aberrant signal transduction pathways in paediatric T-cell Acute Lymphoblastic Leukaemia (T-ALL) 65
Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK) 55
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 55
Cellular senescence in vascular wall mesenchymal stromal cells, a possible contribution to the development of aortic aneurysm 53
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells 52
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 52
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 50
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 48
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications 48
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 47
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 47
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 46
Assessment of the structural and functional characteristics of human mesenchymal stem cells associated with a prolonged exposure of morphine 46
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response 46
Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression 46
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 45
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 45
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 45
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment 45
Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL) 45
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia 43
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics 43
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications 43
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a 43
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells 42
13. PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation 42
Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model 41
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 40
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 40
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS 40
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 40
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 40
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines 39
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 39
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia 39
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 39
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells 38
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 37
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis 37
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels 36
Current treatment strategies for inhibiting mTOR in cancer 36
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 35
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance 35
Therapeutic targeting of CK2 in acute and chronic leukemias 35
Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies 35
Implication of Cellular Senescence in Osteoarthritis: A Study on Equine Synovial Fluid Mesenchymal Stromal Cells 35
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML 34
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update 33
Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells 33
Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells 33
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside 33
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 33
K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway 32
Targeting the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in acute myelogenous leukaemia 32
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 32
Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 32
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia 32
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 32
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies 31
GSK-3: a multifaceted player in acute leukemias 31
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia 31
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology 31
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage 30
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 30
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 29
The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias 29
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 29
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia 29
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 29
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy 29
The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia 28
Dual inhibition of class IA phoshatidylinositol 3-kinase and mTOR as a new therapeutic option for T-cell acute lymphoblastic leukemia 28
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 28
Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients 28
Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib 28
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells 27
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias 27
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 26
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms 25
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 25
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 25
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 24
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia 24
Advances in Targeting Signal Transduction Pathways 6
Totale 3.940
Categoria #
all - tutte 45.245
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.245


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202039 0 0 0 0 0 0 0 10 8 7 7 7
2020/2021132 8 5 10 14 5 19 12 15 10 7 14 13
2021/202290 3 6 4 13 2 4 8 7 8 7 18 10
2022/2023551 7 11 12 27 42 70 30 62 102 26 59 103
2023/2024909 35 28 42 150 125 66 177 62 26 28 87 83
2024/20252.111 88 19 13 231 877 648 110 125 0 0 0 0
Totale 3.940